A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Study Identifier:
ART0380C001
CT.gov Identifier:
NCT04657068
EudraCT Identifier:
202100000000
EU Trial (CTIS) Number:
2024-511534-12-00
Study Contact Information:
(210) 593-5651 or [email protected]
Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

To evaluate a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to:

Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine

Learn more about the side effects of ART0380 alone and in combination with gemcitabine

Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine.

To evaluate the safety, tolerability, PK and preliminary efficacy of ART0380 as monotherapy or in combination with gemcitabine in participants with advanced or metastatic solid tumors, advanced or solid tumors that fail to express Ataxia-Telangiectasia Mutated protein kinase (ATM) by immunohistochemistry, and high grade serous ovarian, primary peritoneal or fallopian tube carcinoma.

To measure ?H2AX levels in circulating tumor cells (CTC’s) and normal cells (PBMC’s).

Part A: To assess the safety and tolerability of ART0380 given orally in patients with advanced or metastatic solid tumors and to determine the maximum tolerated doses (MTDs) and/or recommended Phase II doses/schedules (RP2Ds) of ART0380 as monotherapy or in combination with gemcitabine or in combination with irinotecan.

Part B1: To further assess the safety and tolerability of ART0380 given orally as monotherapy at RP2Ds.

Part B2: To compare the efficacy of ART0380 in combination with gemcitabine compared with gemcitabine alone in patients with high grade serous ovarian, primary peritoneal or fallopian tube carcinoma that is resistant to platinum (PFI <6 months).

Key study objectives included evaluation of safety and tolerability, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics.

To assess the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ART0380

Ataxia-telangiectasia-mutated (ATM) deficiency identified by Artios’ ATR-ID algorithm (bespoke algorithm to predict ATM protein deficiency using mutational impact) or IHC H-score ≤10, or percentage staining at 0 in ≥90% of tumor cells.

Cancers with molecular alterations presumed to cause replication stress identified by Artios’ DcoDeR platform

To study development approach wherein tumor cells experience a triple combination of biological insults: induced RS by irinotecan, endogenous RS via ataxia-telangiectasia mutated (ATM) loss, and prevention of rescue from RS by ATR inhibition

Key objectives included safety, tolerability, and preliminary efficacy.

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
  • Unspecified Cancer
  • Metastatic Cancer
  • Ovarian
  • Primary Peritoneal
  • Fallopian Tube
  • Endometrial
  • Bowel (Colorectal)
  • Pancreas
  • Acinar Cell
    • Phase
    The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
    I/II
    Sex
    Female & Male
    Age
    18+ years
    Study Drug
  • Drug: Experimental: Part A1
    • Study Status
    Indicates the current recruitment status or the expanded access status
    Recruiting

    Requirements information
    Inclusion criteria
    • General Inclusion Criteria:
    • Signed informed consent
    • Discontinued all previous treatments for cancer for at least 21 days or 5 half-lives, whichever is shorter, and recovered from the acute effects of therapy to CTCAE Grade ≤1. Palliative radiotherapy must have completed 1 week prior to start of study treatment.
    • If patients have a known germline BRCA mutation or a cancer with a somatic BRCA mutations or which is HRD positive and for which there is an approved PARP inhibitor, participants should have received such treatment before participating in the study unless contra-indicated
    • At least 1 radiologically evaluable lesion (measurable and/or non-measurable) that can be assessed at baseline and is suitable for repeated radiological evaluation by RECIST v1.1 or Prostate Cancer Working Group-3 Guidelines (PCWG-3)
    • Acceptable hematologic, renal, hepatic, and coagulation functions independent of transfusions and granulocyte colony-stimulating factor
    • Non-irradiated tumor tissue sample (archival or newly obtained core biopsy of a tumor lesion) available for submission for analysis.
    • Female patients of childbearing potential and male patients with female partners of childbearing potential are required to use highly effective contraception plus one barrier method during their participation in the study and for 7 months and 5 months respectively following the last dose. For male and female patients given gemcitabine or irinotecan, highly effective contraception plus one barrier method must be used from study entry until 6 months after the last dose of study treatment. Male patients are required to refrain from donating sperm and female patients are required to refrain from donating eggs, during their participation in the study and for 6 months following last dose.
    • Estimated life expectancy of ≥12 weeks
    • Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
    • Performance status of 0-1 on the ECOG Scale
    • Additional inclusion criteria for participants in dose escalation (Part A1):
    • Advanced or metastatic cancer which is refractory to standard therapies, or for which no standard therapies exist, or for which the investigator feels no other active therapy is required for the duration of the study
    • Performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale
    • Additional inclusion criteria for participants in dose escalation (Part A2):
    • •Advanced or metastatic cancer for which gemcitabine is an appropriate treatment. Prior treatment with gemcitabine is permitted.
    • Additional inclusion criteria for participants in dose escalation (Part A3):
    • Advanced or metastatic cancer for which irinotecan is an appropriate treatment. Prior treatment with irinotecan is permitted.
    • For food effect cohort only: Patients must be able to eat a high-fat meal within a 30 minute period, as provided by the study site.
    • Additional inclusion criteria for participants in dose expansion (Part B1):
    • Patients with advanced or metastatic solid tumors with alterations to the ATM gene likely to predict for loss of ATM protein
    • Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1
    • For France only ART0380 Monotherapy; Patient that is not eligible for curative treatment, for whom all standard of care therapies have failed and no therapies known to provide clinical benefit are available.
    • Combination arms; Patients for which irinotecan is an appropriate treatment. Prior treatment with irinotecan is permitted.
    • For Spain only ART0380 Combination therapy, Patient that is not eligible for curative treatment, for whom standard of care therapies have failed.
    • Additional inclusion criteria for participants in dose expansion (Part B2):
    • Patients with a known germline BRCA mutation, or a cancer with a known somatic BRCA mutation, or which is known to be HRD positive, and for which there is an approved PARP inhibitor should have received such treatment before participating in the study, unless contra-indicated.
    • Females with histologically-confirmed diagnosis of high grade serous carcinoma of the ovary, fallopian tube or primary peritoneum that is not amenable to curative therapy
    • Platinum-resistant disease. Patients must not have had primary platinum-refractory disease (disease that progressed during first-line platinum-based therapy).
    • No more than one prior regimen in the platinum-resistant setting. Hormonal therapies and antiangiogenic therapies (as single agents) and PARP inhibitors used as maintenance therapy are not considered as separate lines of therapy. Patients should have previously received bevacizumab and chemotherapy unless contra-indicated.
    • Have not received prior treatment with gemcitabine unless administered in combination with a platinum with no disease progression within 12 months after completion of that regimen
    • Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1
    • Inclusion criteria specific to Part B3
    • Persistent or recurrent endometrial cancer with biological selection.:
    • Patients should have received taxane/platinum chemotherapy, unless contraindicated.
    • Measurable disease.
    • Inclusion criteria specific to Part B4
    • Advanced or metastatic solid cancers of any histology with biological selection
    • If a PD-1/PDL-1 inhibitor (eg, pembrolizumab) is approved and available for the patient's cancer, the patient should have received such treatment before participating in this study.
    • Radiologically evaluable disease
    • Performance status of 0-1 on the ECOG scale
    • Inclusion criteria specific to Part B5
    • Metastatic CRC with alterations to the ATM gene
    • Participants should have previously received appropriate prior lines of therapy in this setting.
    • Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1.
    • Patients have received a maximum of 2 prior chemotherapy regimens for the treatment of CRC and have demonstrated progressive disease or intolerance to their last regimen.
    • Inclusion criteria specific to Part B6:
    • Metastatic or locally advanced PDAC or acinar cell carcinoma with alterations to the ATM gene
    • Participants must have received a maximum of 1 prior chemotherapy regimen for the treatment of the advanced disease and have demonstrated progressive disease or intolerance to this regimen OR have received neoadjuvant/adjuvant therapy with recurring occurring <6 months following completion of this treatment.
    • Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1. Previously irradiated lesions may not be considered target lesions.
    • Serum albumin ≥3g/dL within 7 days prior to first dose.
    Exclusion criteria
    • General Exclusion Criteria:
    • Women who are pregnant, breast feeding, or who plan to become pregnant while in the study or within 7 months after the last administration of study treatment
    • Men who plan to father a child while in the study or within5 months after the last administration of study treatment
    • Serious concomitant systemic disorder that would compromise the participants ability to adhere to the protocol including: one or more opportunistic HIV/AIDs-related infections within the past 12 months, a known hepatitis B virus, or known hepatitis C virus; documented active or chronic tuberculosis infection; malignancy prior to the one currently being treated that is not in remission
    • Have ongoing interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic).
    • Moderate or severe cardiovascular disease
    • Valvulopathy that is severe, moderate, or deemed clinically significant
    • Documented major electrocardiogram (ECG) abnormalities which are clinically significant
    • Symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment
    • Received a live vaccine within 30 days before the first dose of study treatment
    • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate
    • Recent major surgery within 4 weeks prior to entry into the study or minor surgery within 1 week of entry into the study
    • Drainage for ascites, pleural effusion or pericardial fluid within 4 weeks before the first dose of study treatment.
    • A significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment
    • Currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
    • Additional exclusion criteria for participants in dose escalation (Part A3, B1, B5, and B6 in combination with irinotecan):
    • Patients who have symptoms or signs of clinically unacceptable deterioration of the primary disease at the time of screening.
    • Patients who are known to be homozygous for both UGT1A1 *6 and *28 (UGT1A1 7/7 genotype), or simultaneously heterozygous for both UGT1A1 *6 and *28.
    • Patients receiving strong inhibitors of UGT1A1 within 2 weeks before the first dose of study treatment
    • Part A3 Fed-fasted cohort only: Patients receiving acid reducing agents within 1 week before the first dose of study treatment will be excluded
    • Part B6: Neuroendocrine (carcinoid, islet cell) or adenosquamous carcinoma pancreatic cancer

    Clinical Study Information for Healthcare Providers

    By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

    View Study Information

    Study Locations

    Location
    Investigator
    Status
    Condition(s) Treated at Site
    Location
    START Madrid, Spain (FJD)
    Madrid, Spain, 28040
    Investigator
    Bernard Doger de Speville
    Status
    Recruiting
    Condition(s) Treated at Site
    Unspecified Cancer
    Metastatic Cancer
    Ovarian
    Primary Peritoneal
    Fallopian Tube
    Endometrial
    Bowel (Colorectal)
    Pancreas
    Acinar Cell
    Location
    START La Rioja
    Logroño, La Rioja, Spain, 26006
    Investigator
    Maria de Miguel
    Status
    Recruiting
    Condition(s) Treated at Site
    Unspecified Cancer
    Metastatic Cancer
    Ovarian
    Primary Peritoneal
    Fallopian Tube
    Endometrial
    Bowel (Colorectal)
    Pancreas
    Acinar Cell
    Location
    START Madrid, Spain (CIOCC)
    Madrid, Spain, 28050
    Investigator
    Irene Moreno
    Status
    Recruiting
    Condition(s) Treated at Site
    Unspecified Cancer
    Metastatic Cancer
    Ovarian
    Primary Peritoneal
    Fallopian Tube
    Endometrial
    Bowel (Colorectal)
    Pancreas
    Acinar Cell